Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



1 Must-Watch Drug Tomorrow

While Regeneron  (Nasdaq: REGN  )  doesn't rank among top performers in the Nasdaq Composite, its year-to-date performance is still nothing short of impressive. Shares have risen around 180% and boosted the company's market capitalization to nearly $15 billion on the strength of Eylea, the company's flagship drug targeting age-related macular degeneration. The company reports earnings Wednesday, and as is the case for many high-flying stocks, hitting Wall Street's revenue estimates and offering strong guidance for the future will play a vital role in the direction shares take.

In the following video, health care bureau chief Brenton Flynn outlines the competitive environment for Regeneron's Eylea, including one low-priced drug that could turn out to be its biggest competition.

When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2071197, ~/Articles/ArticleHandler.aspx, 10/21/2016 11:05:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,070.93 -91.42 -0.50%
S&P 500 2,135.78 -5.56 -0.26%
NASD 5,245.25 3.41 0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 10:49 AM
ARNA $1.60 Up +0.01 +0.63%
Arena Pharmaceutic… CAPS Rating: **
NVS $75.22 Down -0.70 -0.92%
Novartis CAPS Rating: ****
REGN $365.35 Down -5.89 -1.59%
Regeneron Pharmace… CAPS Rating: ****
RHHBY $29.22 Down -0.02 -0.05%
Roche Holding Ltd.… CAPS Rating: *****
SRPT $48.42 Down -0.63 -1.28%
Sarepta Therapeuti… CAPS Rating: **